Radar · Oncology in China
Best Oncology Companies in China
The 320 best Oncology companies in China in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Abogen Biosciences.
By Rohit KhannaTrends & Stories
320companies tracked
$16.2Bdisclosed funding
3unicorns
187have raised
China's Oncology sector is one of the most aggressively funded corners of global biotech right now, and this directory ranks the best companies operating in it by disclosed equity funding and recent momentum. We're tracking 320 companies with $16.2B in total disclosed capital behind them, three unicorns in the mix, and a global market that's forecast to reach $668.3B by 2034 at an 11.5% CAGR. That's not background noise. That's a structural shift.
The funding distribution is uneven, and that's the story worth watching. Clover Biopharma leads the directory at $400M raised, with D3 Bio ($262M) and OriCell Therapeutics ($170M) well clear of the pack. Lilly Asia Ventures, Qiming, and Hillhouse are the names showing up most consistently on cap tables. So where's the heat concentrated? China's oncology drug pipeline has scaled fast on biomarker-driven targeting and angiogenesis inhibitors, and as shown in 2019 research, patient support frameworks are increasingly baked into treatment design, not bolted on after. Cost-containment pressure from Beijing's reimbursement policies keeps margins tight, but it's also forcing companies toward differentiated science. You can see that discipline reflected in who's raised what here.
Sources & further reading
- Pharma 50 Deep Dive: Oncology leads with $110B in sales; GLP-1s contin
- Oncology Market Value to More Than Double, Reaching USD 748.17 Billion
FLIAR INTELLIGENCE · ONCOLOGY × CHINA
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
86%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
298kcombined LinkedIn audience
71%of audience held by top 3
3companies hiring publicly (12 mo)
Ranked: Best Oncology companies in China
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Abogen Biosciences 🦄 Developer of mRNA-based therapeutics for cancer and infectious diseases 55Moat top 14%Patents top 17%Innovation top 22%Funding top 27% All 8 signals ▾Moattop 14% Patentstop 17% Innovationtop 22% Fundingtop 27% Talenttop 38% Marketbottom 44% Globalbottom 43% Techbottom 24% Moat: Editorial + unicorn rating 9/10 · IP moat: 157 patents Patents: 157 patents matched (strict assignee match) · 154 filings since 2022 vs 3 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $1.1B | 49 mo ago | Series C | — | Dr InBev Co-Founder & Co-CEO | — | 157 patents mRNA and circular RNA therapeutics with lipid nanoparticle delivery systems | — |
| 2 | Innovent Bio Developer of antibody therapeutics for multiple diseases | $535M | 46 mo ago | Public | 5,144 | Michael Yu Founder & CEO | 9 signals ▼55% Regulatory · Earnings · Funding | — | 1 partnership |
| 3 | CStone Pharma Developing and licensing novel drugs for diseases including cancer and autoimmune diseases | $410M | 68 mo ago | Public | 476 | — | — | — | 1 partnership |
| 4 | Clover Biopharma Developer of drugs to treat autoimmune, cancer and infectious diseases 67Funding top 13%Market top 25%Global top 44%Moat top 48% All 6 signals ▾Fundingtop 13% Markettop 25% Globaltop 44% Moattop 48% Newsbottom 32% Techbottom 24% Funding: Raised $400M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) Market: 681 employees (top 2% of Life Sciences) · Serving 4 countries incl. United States, China, United Kingdom rank vs industry peers · Fliar Intelligence Index 67/100 | $400M | 2 mo ago | Public | 681 | — | — | — | — |
| 5 | Tianjing Biological Developer of immuno-oncology drugs for treating cancer and autoimmune diseases 55Funding top 21%Market top 41%Moat top 48%Talent bottom 49% All 7 signals ▾Fundingtop 21% Markettop 41% Moattop 48% Talentbottom 49% Globalbottom 46% Techbottom 45% Newsbottom 21% Funding: Raised $380M across 5 rounds · 5 rounds over 9 yrs (0.6/yr) Market: 318 employees (top 5% of Life Sciences) · Top-10,000,000 web property rank vs industry peers · Fliar Intelligence Index 55/100 | $380M | 28 mo ago | Public | 318 | Yan Jingwu Chairman & CEO | — | — | — |
| 6 | 3DMed Provider of personalized diagnostic treatment solutions for cancer | $365M | 67 mo ago | Series D | 215 | Simon Shung Founder | — | — | — |
| 7 | Avistone Developer of precision therapeutics for oncology 32Funding top 26%Moat top 38%Talent bottom 49%Market bottom 37% All 5 signals ▾Fundingtop 26% Moattop 38% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $340M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 32/100 | $340M | 29 mo ago | Series B | — | Shi Hepeng Founder & CEO | — | — | — |
| 8 | HaiHe Biopharma Developer of reformulations for cancer treatment | $333M | 46 mo ago | Series B | 181 | Ruiping Dong CEO | — | 90 patents Small-molecule inhibitors for oncology targets (PARP1, AR, MAT2A, SOS1, ENPP1) and formulations. | — |
| 9 | LianBio Developer of therapeutics for cardiorenal and oncology diseases | $313M | 62 mo ago | Public | 163 | Bing Li CEO | — | — | — |
| 10 | Harbour BioMed Developer of antibody therapeutics in immunology and oncology disease | $313M | 71 mo ago | Public | 167 | Jingsong Wang Founder | 8 signals ▼27% Leadership · Earnings · M&A | 241 patents Bispecific antibody therapeutics targeting immune checkpoints and tumor antigens | 2 launchs · 1 partnership |
| 11 | CARsgen Developer of CAR-T cell therapies for the treatment of hematological malignancies and solid tumors | $276M | 67 mo ago | Public | 525 | Huamao Wang Co-Founder & COO | — | — | — |
| 12 | D3 Bio Developer novel therapeutics for cancer 40Funding top 20%Growth top 35%Talent bottom 49%Moat bottom 48% All 7 signals ▾Fundingtop 20% Growthtop 35% Talentbottom 49% Moatbottom 48% Techbottom 40% Globalbottom 38% Marketbottom 28% Funding: Raised $262M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 40/100 | $262M | 6 mo ago | Series B | — | George Chen Founder & CEO | — | — | — |
| 13 | Elpiscience Developer of checkpoint inhibitors for the treatment of cancer | $260M | 61 mo ago | Series C | 150 | — | — | — | — |
| 14 | Adlai Nortye Developer of immune oncolytic therapies for treating cancer | $253M | 59 mo ago | Public | 27 27 → 63 (+133%) | Carsten Lu Founder & ceo | 4 signals Funding · Earnings | 190 patents Targeted oncology therapeutics: small‑molecule degraders, kinase inhibitors, and antibody‑drug conjugates | — |
| 15 | Genecast Non-invasive diagnosis and monitoring of cancer | $246M | 67 mo ago | Series E | — | Ma Guosheng Co-Founder & VP | — | — | 1 job opening · 1 partnership |
| 16 | Guangzhou Kang Liming Biotechnology Provider of cancer detection kits | $220M | 56 mo ago | Series D | — | Hongzhi Zou Founder and Chairman | — | — | — |
| 17 | Hutchison China MediTech Developer of immunotherapies for the treatment of cancer and immunological diseases | $215M | 51 mo ago | Public | 1,990 | — | — | — | 1 award |
| 18 | BioRay Pharmaceutical 🦄 Developer of therapeutics for immunology and oncology | $215M | 41 mo ago | Acquired | 8 | Haibin Wang CEO | — | — | — |
| 19 | Singlera Genomics Developer of the NGS-based platform to detect cancer 72Moat top 21%Funding top 26%Market top 30%Patents top 33% All 6 signals ▾Moattop 21% Fundingtop 26% Markettop 30% Patentstop 33% Innovationtop 41% Globalbottom 40% Moat: Editorial + unicorn rating 8/10 · IP moat: 29 patents Funding: Raised $209M across 5 rounds · 5 rounds over 8 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 72/100 | $209M | 23 mo ago | Series B | 300 | — | — | 29 patents Liquid biopsy DNA methylation biomarkers for cancer detection and tumor assessment | — |
| 20 | Souzhou Ribo Life Science Developer of nucleic acid drugs based on RNA interference (RNAi) technology | $201M | 46 mo ago | Public | 228 | Zicai Liang Founder | — | — | — |
| 21 | Kelun Biotech Developer of therapeutics for cancer treatment | $200M | 41 mo ago | Public | 1,309 | Junyou Ge CEO | — | 691 patents Developing antibody-drug conjugates and small-molecule oncology therapeutics. | — |
| 22 | Gracell Bio Developer of CAR T cell therapies for the treatment of cancer | $195M | 34 mo ago | Acquired | 9 | Wei Cao Founder & CEO | — | — | — |
| 23 | Akeso Developer of antibody drug conjugates for the treatment of broad spectrum diseases 57Funding top 20%Growth top 35%News top 39%Market top 40% All 8 signals ▾Fundingtop 20% Growthtop 35% Newstop 39% Markettop 40% Moattop 48% Talentbottom 41% Globalbottom 38% Techbottom 35% Funding: Raised $195M across 4 rounds · 4 rounds over 11 yrs (0.4/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 57/100 | $195M | 20 mo ago | Public | 2,520 | Michelle Xia CEO & President | — | — | 1 launch · 1 award |
| 24 | KeyMed Biosciences Developer of antibody-based therapeutics for cancer and autoimmune diseases | $190M | 47 mo ago | Public | 750 | Bo Chen CEO | — | 101 patents Patents concentrated in health & consumer products | — |
| 25 | Canbridge Life Sciences Developer of therapeutics for rare diseases and cancer | $186M | 60 mo ago | Public | 17 | — | — | — | — |
| 26 | IASO BIO Provider of pharmaceuticals for cell therapies for oncology | $178M | 41 mo ago | Series C | 400 | Jinhua Zhang Co-Founder & CEO | — | — | — |
| 27 | OriCell Therapeutics Developer of immuno-therapeutics for cancer treatment 72Funding top 16%Patents top 27%Moat top 28%Innovation top 34% All 8 signals ▾Fundingtop 16% Patentstop 27% Moattop 28% Innovationtop 34% Newstop 36% Markettop 37% Talentbottom 49% Globalbottom 43% Funding: Raised $170M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) Patents: 56 patents matched (strict assignee match) · 55 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 72/100 | $170M | 2 mo ago | Series D | 150 | He Xiaowen Co-Founder | 3 signals Funding | 56 patents Patents concentrated in health & consumer products | — |
| 28 | Laekna Developer of therapeutics for cancer and liver fibrosis | $168M | 49 mo ago | Public | — | Chris Lu Founder And Ceo | — | 12 patents Combination pharmaceutical formulations for cancer therapy | 1 partnership |
| 29 | GenFleet Therapeutics Developer of drugs for treating tumors and autoimmune diseases | $166M | 53 mo ago | Public | — | Jiong Lan Co-Founder & CEO | — | 210 patents Design and synthesis of small‑molecule kinase inhibitors, macrocycles, and antibody‑drug conjugates for oncology. | — |
| 30 | Binhui Bio Developer of oncolytic virus-based drugs | $158M | 49 mo ago | Series C | — | Liu Binlei Founder & CEO | — | — | — |
| 31 | Adagene Developer of immunotherapy for the treatment of cancer 37Funding top 18%Product top 24%Moat top 38%Tech top 42% All 12 signals ▾Fundingtop 18% Producttop 24% Moattop 38% Techtop 42% Globaltop 43% Partnerstop 45% Patentstop 46% Talentbottom 49% Growthbottom 42% Innovationbottom 38% Marketbottom 36% Newsbottom 23% Funding: Raised $157M across 5 rounds · 5 rounds over 12 yrs (0.4/yr) Product: 2 distinct product lines · Company stage: Public rank vs industry peers · Fliar Intelligence Index 37/100 | $157M | 11 mo ago | Public | 15 | Peter Luo Founder & CEO | — | 26 patents Antibody library engineering and heterodimeric Fc protein therapeutics for cancer treatment | — |
| 32 | TYK Medicines Developer of drugs for the treatment of cancer | $154M | 29 mo ago | Public | 100 | Wu Yusheng Founder & CEO | — | 164 patents Patents concentrated in chemistry & materials | — |
| 33 | New Element Medicine Developer of drugs for various cancer | $152M | 32 mo ago | Series D | — | Shi Dongfang Founder & CEO | — | — | — |
| 34 | Legend Biotechnology Developer of cell therapy to treat cancer and infectious diseases | $150M | 38 mo ago | Public | 1,576 | Yuan Xu CEO | 18 signals Announcements · Earnings · Leadership | — | — |
| 35 | Impact Therapeutics Developer of small molecule therapeutics for the treatment of cancer 50Patents top 18%Funding top 21%Innovation top 23%Moat top 26% All 6 signals ▾Patentstop 18% Fundingtop 21% Innovationtop 23% Moattop 26% Globalbottom 43% Marketbottom 26% Patents: 226 patents matched (strict assignee match) · 118 filings since 2022 vs 76 in 2017-21 Funding: Raised $145M across 5 rounds · 5 rounds over 12 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $145M | 19 mo ago | Public | 7 | — | — | 226 patents Small-molecule inhibitors of PARP, kinases, and DHX9 for cancer therapy | — |
| 36 | Immorna Developer of mRNA-based therapeutics for cancer and other diseases 14Funding top 29%Moat top 38%Talent bottom 49%Global bottom 36% All 6 signals ▾Fundingtop 29% Moattop 38% Talentbottom 49% Globalbottom 36% Marketbottom 25% Techbottom 24% Funding: Raised $115M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 5/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 14/100 | $115M | 21 mo ago | Series A | — | Zihao Wang CEO | — | — | — |
| 37 | Xiantong Pharmaceutical Developer of radiopharmaceuticals for the diagnosis of tumors, neurodegenerative diseases and cardiovascular… | $100M | 35 mo ago | Series E | 400 | — | — | — | — |
| 38 | Evopoint Developer of therapeutics for multiple diseases | $97M | 27 mo ago | Series E | — | Nianfeng Ju Co-Founder | — | — | — |
| 39 | Pyrotech Manufacturer of therapeutics for inflammatory and oncology conditions | $97M | 24 mo ago | Series A | 10 | TJ Deng Co-Founder & CEO | — | 2 patents Innovative star-shaped glass curtain wall façade modules for architectural building envelopes. | — |
| 40 | Full-Life Technologies Provider of discovery, development, production, and logistics services for of nuclear medicines 48Funding top 17%Talent top 28%Patents top 33%Growth top 35% All 9 signals ▾Fundingtop 17% Talenttop 28% Patentstop 33% Growthtop 35% Innovationtop 45% Moattop 47% Globalbottom 45% Marketbottom 32% Techbottom 22% Funding: Raised $94.3M across 8 rounds · 8 rounds over 5 yrs (1.6/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 48/100 | $94M | 1 mo ago | Series D | — | HH Ting Co-Founder And Chief Strategy Officer | — | 24 patents Targeted radiopharmaceuticals and antibody therapeutics for cell‑surface receptors | — |
| 41 | Biosion Developer of antibody-based therapeutics to treat various diseases | $76M | 37 mo ago | Series B | 90 | Mingjiu Chen Founder & Chairman &CEO | — | 131 patents Therapeutic antibodies and fusion proteins for immune checkpoint and tumor antigen targeting | 1 launch |
| 42 | GRIT Biotechnology Developer of cell therapy to treat solid tumours | $75M | 33 mo ago | Series B | — | Liu Yarong Founder & CEO | — | 56 patents Engineered immune cell therapies and multispecific biologics for cancer immunotherapy | — |
| 43 | Prenetics Online platform for genetic and diagnostic health testing that helps identify health risks 67Funding top 22%Tech top 30%News top 31%Talent top 33% All 10 signals ▾Fundingtop 22% Techtop 30% Newstop 31% Talenttop 33% Growthtop 34% Moattop 37% Markettop 38% Globaltop 44% Innovationbottom 34% Patentsbottom 31% Funding: Raised $67.7M across 5 rounds · 5 rounds over 12 yrs (0.4/yr) Tech: 51 technologies across 5/8 capability areas · Cloud: Akamai, Amazon Web Services rank vs industry peers · Fliar Intelligence Index 67/100 | $68M | 7 mo ago | Public | 400 | Michael Yang Co-Founder And Scientific Advisor | 19 signals ▲36% Earnings · Funding · Announcements | 8 patents Integrated enzyme pellet platforms for rapid nucleic acid diagnostic testing | — |
| 44 | Accropeutics Developer of drugs for inflammation, autoimmune diseases, and cancer 57Funding top 20%Talent top 38%Market bottom 49%Global bottom 48% All 4 signals ▾Fundingtop 20% Talenttop 38% Marketbottom 49% Globalbottom 48% Funding: Raised $62.0M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 57/100 | $62M | 1 mo ago | Series C | — | Xiaohu Zhang Co-Founder & CEO | — | — | — |
| 45 | Phrontline Biopharma Developer of therapeutics for various diseases 64Talent top 28%Funding top 29%Global bottom 48% All 3 signals ▾Talenttop 28% Fundingtop 29% Globalbottom 48% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $60.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 64/100 | $60M | 6 mo ago | Seed | — | Siyi Hu Co-Founder | — | — | — |
| 46 | Yantai Lannacheng Biotechnology Developer of radiopharmaceuticals for molecular imaging and nanomedicine | $41M | 25 mo ago | Series B | — | Chen Xiaoyuan Co-Founder | — | 78 patents Targeted radiopharmaceuticals and bispecific antibodies for FAP/PSMA cancer imaging and therapy | — |
| 47 | Conjustar Developer of drug conjugates for the treatment of cancer | $28M | 28 mo ago | Seed | — | Shuyi Tang CEO | — | — | — |
| 48 | Starna Therapeutics Developer of RNA-based drugs for multiple diseases 29Funding top 34%Moat top 38%Talent bottom 49%Market bottom 37% All 5 signals ▾Fundingtop 34% Moattop 38% Talentbottom 49% Marketbottom 37% Globalbottom 36% Funding: Raised $22.1M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $22M | 7 mo ago | Series B | — | Rongkuan Hu Founder | — | — | — |
| 49 | CNRT Provider of medical isotopes for diagnosis and treatment of malignant tumors 62Talent top 28%Funding top 33%Market top 40%Moat top 42% All 5 signals ▾Talenttop 28% Fundingtop 33% Markettop 40% Moattop 42% Globalbottom 36% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $16.9M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $17M | 2 mo ago | Series E | 100 | Maoliang Li Co-Founder & Chairman | — | — | — |
| 50 | Nk-Celltech Provider of immuno-oncologic drugs for cancer 40Market top 45%Funding top 46%Global bottom 38% All 3 signals ▾Markettop 45% Fundingtop 46% Globalbottom 38% Market: 60 employees (top 31% of Life Sciences) Funding: Raised $14.9M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $15M | 11 mo ago | Series A | 60 | — | — | — | — |
Top 12 Oncology companies in China
#1
Public · Chengdu, Sichuan Sheng · founded 2007 · 681 employees$400Mraised▾
Public · Chengdu, Sichuan Sheng · founded 2007 · 681 employees
Developer of drugs to treat autoimmune, cancer, and infectious diseases. The company has developed its proprietary Trimer-Tag technology to develop novel, trimerized fusion-protein therapies. The trimerized fusion proteins have been shown to have a much better binding and therapeutic response. The company's drug pipeline include SCB-808, in a ready-for-injection prefilled syringe formulation and SCB-313 for Oncology.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 13%Market
top 25%Global
top 44%Moat
top 48%News
bottom 32%Tech
bottom 24%Funding: Raised $400M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) · Last round Post IPO (Mar 2026)
Market: 681 employees (top 2% of Life Sciences) · Serving 4 countries incl. United States, China, United Kingdom
Global: Serving 4 countries incl. United States, China, United Kingdom · Investors from 3 countries beyond China
Audience (LinkedIn): 8k LinkedIn followers — 2.6% of this cohort's audience
Funding rounds
- Mar 2026Post IPO$3.6M
- Apr 2024Post IPO$320.7K
- May 2023Post IPO$48.9M
- Dec 2022Post IPO$64.4M
Investors
GL Ventures, Temasek, Delos Capital, Orbimed, Oceanpine Capital, Qiaojing Capital
Tech stack
PhpTengineSwiperJqueryHsts
#2
Series D · Shanghai, Shanghai · founded 2021$94.3Mraised▾
Series D · Shanghai, Shanghai · founded 2021
Provider of discovery, development, production, and logistics services for of nuclear medicines. The Company endeavors to tackle fundamental challenges affecting radiopharmaceuticals. It manufactures radiopharmaceutical drug products.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 17%Talent
top 28%Patents
top 33%Growth
top 35%Innovation
top 45%Moat
top 47%Funding: Raised $94.3M across 8 rounds · 8 rounds over 5 yrs (1.6/yr) · Last round Series D (May 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Patents: 24 patents matched (strict assignee match) · 24 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 7k LinkedIn followers — 2.4% of this cohort's audience
Activity (LinkedIn): 1 awards · 1 expansions announced in 12 mo
Funding rounds
- May 2026Series D$110M
- May 2026Conventional Debt$40M
- Sep 2025Series C$50M
- Sep 2025Conventional Debt$27M
Founders & team
Investors
Prosperity7 Ventures, Sky9 Capital, Summer Capital, Chengwei Capital, Junson Capital, Guanghua Wutong Fund
Tech stack
Alibaba Cloud CdnAnimate.CssBaidu Analytics (百度统计)BootstrapJqueryNginx
#3
Series D · Pudong, Shanghai · founded 2015 · 150 employees$170Mraised▾
Series D · Pudong, Shanghai · founded 2015 · 150 employees
Developer of immuno-therapeutics for cancer treatment. It offers CAR-T- based therapies and antibodies for the treatment of liver cancer, ovarian cancer, gastric cancer, cervical cancer, non-small cell lung cancer, and others.
Fliar Intelligence Index™ 72how this company ranks against its industry peers
Funding
top 16%Patents
top 27%Moat
top 28%Innovation
top 34%News
top 36%Market
top 37%Funding: Raised $170M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) · Last round Series D (Apr 2026)
Patents: 56 patents matched (strict assignee match) · 55 filings since 2022 vs 1 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 8/10 · IP moat: 56 patents · Soonicorn
Audience (LinkedIn): 3k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: TCE Senior Scientist, Senior Scientist (In vivo CAR-T)
Funding rounds
- Apr 2026Series D$110M
- Jan 2026Series C$70M
- Feb 2023Series B$45M
- Aug 2022Series B$125M
Founders & team
Investors
RTW Investments, Qatar Investment Authority, Qiming Venture Partners, C&D, Quan Capital, Sinopharm Capital
#4
Series C · Suzhou, Jiangsu · founded 2017$62Mraised▾
Series C · Suzhou, Jiangsu · founded 2017
Developer of drugs for inflammation, autoimmune diseases, and cancer. The pipeline includes AC-003 Receptor -interacting protein kinase1 for Idiopathic pulmonary fibrosis, Graft versus Host Disease, AC-101 for inflammatory bowel disease, AC-201, an allosteric TYK2/JAK1 inhibitor for psoriasis, and others.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 20%Talent
top 38%Market
bottom 49%Global
bottom 48%Funding: Raised $62.0M across 2 rounds · 2 rounds over 1 yrs (2.0/yr) · Last round Series C (May 2026)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Audience (LinkedIn): 131 LinkedIn followers
Funding rounds
- May 2026Series C$50M
- Mar 2025Series B$12M
Founders & team
Investors
Shenzhen Capital Group, Morningside, Suzhou Industrial Park Leading Venture Capital, Hefei Sci-Tec, Orbimed, TCG Crossover
#5
Series B · Shanghai, Shanghai · founded 2018$262Mraised▾
Series B · Shanghai, Shanghai · founded 2018
Developer novel therapeutics for cancer. The company is focusing on developing innovative medicines in oncology and immunology. The company's pipeline include D3S-001 for the treatment of advanced unresectable or metastatic colorectal cancers.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Funding
top 20%Growth
top 35%Talent
bottom 49%Moat
bottom 48%Tech
bottom 40%Global
bottom 38%Funding: Raised $262M across 3 rounds · 3 rounds over 6 yrs (0.5/yr) · Last round Series B (Dec 2025)
Growth: Fresh capital in last 24 mo
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Funding rounds
- Dec 2025Series B$108M
- Apr 2024Series A$62M
- Nov 2020Series A$200M
Founders & team
Investors
Medicxi, WuXi AppTec, Matrix Partners China, Boyu Capital, Sequoia Capital China, Temasek
Tech stack
CloudflareGoogle AnalyticsHstsHttp/3JqueryMicrosoft 365
#6
Series E · Chengdu, Sichuan Sheng · founded 2016 · 100 employees$16.9Mraised▾
Series E · Chengdu, Sichuan Sheng · founded 2016 · 100 employees
Chengdu Nuruit Medical Technology provides medical isotopes for diagnosis and treatment of malignant tumors. It also offers radiopharmaceuticals technology. The company is also involved in providing nuclear medicine-related technical and scientific consulting services. It has completed a pilot plant project in radiopharmaceuticals based treatment of cancer. It also has several patents like phosphonium carbon microspheres, phosphorus-32 carbon microsphere, iodine-131 carbon microsphere, and 钇-90 carbon microsphere.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Talent
top 28%Funding
top 33%Market
top 40%Moat
top 42%Global
bottom 36%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $16.9M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) · Last round Series E (Apr 2026)
Market: 100 employees (top 20% of Life Sciences)
Funding rounds
- Apr 2026Series E$145M
- Oct 2025Series D$112.3M
- Mar 2024Series C—
- Jul 2019Series B$16.9M
Founders & team
Investors
STAR Capital Partnership, Neovision Capital, Chengdu Tianfu International Biocity Development Group Co., Ltd, Chengdu Industrial Investment Group, Fujian Huaxing Venture Capital, Shenzhen Capital Group
#7
Public · Hong Kong, Hong Kong · founded 2009 · 400 employees$67.7Mraised▾
Public · Hong Kong, Hong Kong · founded 2009 · 400 employees
Online platform for genetic and diagnostic health testing that helps identify health risks. The company has developed Covid-19 PCR tests and rapid test kits and analyzes the samples by using whole-genome sequencing technology. Also, it has developed a DNA screening test for detecting colon cancer.
Fliar Intelligence Index™ 67how this company ranks against its industry peers
Funding
top 22%Tech
top 30%News
top 31%Talent
top 33%Growth
top 34%Moat
top 37%Funding: Raised $67.7M across 5 rounds · 5 rounds over 12 yrs (0.4/yr) · Last round Post IPO (Oct 2025)
Tech: 51 technologies across 5/8 capability areas · Cloud: Akamai, Amazon Web Services · Devops: Varnish
News: 19 BI events in 12 mo (of 86 tracked, 9 types) · +36% YoY · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo
Funding rounds
- Oct 2025Post IPO$48M
- Jul 2024Post IPO—
- Sep 2020Series B$15M
- Oct 2017Series B$40M
Founders & team
Investors
500 Global, COENT Venture Partners, SXE Ventures, Beyond Ventures, Alibaba Entrepreneurs Fund, Ping An Ventures
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#8
Public · Suzhou, Jiangsu · founded 2012 · 15 employees$157.4Mraised▾
Public · Suzhou, Jiangsu · founded 2012 · 15 employees
Developer of immunotherapy for the treatment of cancer. It is developing antibodies which include ADG106 which is an agonist for CD137 in metastatic solid tumors, ADG126 targets CTLA4 for cancer therapy, and aADG116 targets epitope of CTLA4 in metastatic solid tumors and relapsed/refractory non-Hodgkin’s lymphoma.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 18%Product
top 24%Moat
top 38%Tech
top 42%Global
top 43%Partners
top 45%Funding: Raised $157M across 5 rounds · 5 rounds over 12 yrs (0.4/yr) · Last round Post IPO (Jul 2025)
Product: 2 distinct product lines · Company stage: Public
Moat: Editorial + unicorn rating 5/10 · IP moat: 26 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 5k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Incyte) announced in 12 mo
Funding rounds
- Jul 2025Post IPO$25M
- Jan 2020Series D$69M
- Mar 2018Series C$50M
- Jan 2016Series B$28M
Founders & team
Investors
General Atlantic, Eight Roads Ventures, F-Prime Capital, Sequoia Capital, 6 Dimensions Capital, Fidelity
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#9
Seed · Pudong, Shanghai · founded 2022$60Mraised▾
Seed · Pudong, Shanghai · founded 2022
Developer of therapeutics for various diseases. It offers a proprietary dual linker payload ADCs that are delivered to and concentrated in the tumor microenvironment, and bispecific dual payload ADCs that have the benefits of dual targeting that dilever two different MOA of payloads to cancel cells simultaneously.
Fliar Intelligence Index™ 64how this company ranks against its industry peers
Talent
top 28%Funding
top 29%Global
bottom 48%Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Funding: Raised $60.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Nov 2025)
Global: Investors from 1 country beyond China
Funding rounds
- Nov 2025Seed$60M
Founders & team
Investors
Lapam Capital, Guofang Innovation, Jianxin Capital, Jifeng Ventures, Sino Biopharmaceutical, Decheng Capital
#10
Series B · Suzhou, Jiangsu · founded 2021$22.1Mraised▾
Series B · Suzhou, Jiangsu · founded 2021
Developer of RNA-based drugs for multiple diseases. The company focuses on the development of innovative drugs and vaccines with RNA as the core for infectious diseases, tumor immunology, and metabolic diseases.
Fliar Intelligence Index™ 29how this company ranks against its industry peers
Funding
top 34%Moat
top 38%Talent
bottom 49%Market
bottom 37%Global
bottom 36%Funding: Raised $22.1M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Series B (Oct 2025)
Moat: Editorial + unicorn rating 4/10 · Soonicorn
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 417 LinkedIn followers
Funding rounds
- Oct 2025Series B$44M
- May 2022Series A$22.1M
- Dec 2021Angel—
Founders & team
Investors
LYFE Capital, Source Code Capital, Hony Capital, Hillhouse, Sherpa Healthcare Partners, Hua Chuang Capital
#11
Public · Nanjing, Jiangsu · founded 2009 · 7 employees$145.2Mraised▾
Public · Nanjing, Jiangsu · founded 2009 · 7 employees
Developer of small molecule therapeutics for the treatment of cancer. The company's product line include Senaparib is a PARP inhibitor for ovarian cancer maintenance therapy and small cell lung cancer, meeting primary endpoints in the FLAMES study for superior efficacy and safety. Other assets include WEE1 inhibitor IMP7068, ATR inhibitor IMP9064, and PARP1-selective inhibitor IMP1734 (collaborating with Eikon Therapeutics), alongside additional DDR inhibitors.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Patents
top 18%Funding
top 21%Innovation
top 23%Moat
top 26%Global
bottom 43%Market
bottom 26%Patents: 226 patents matched (strict assignee match) · 118 filings since 2022 vs 76 in 2017-21 · Latest publication 2026
Funding: Raised $145M across 5 rounds · 5 rounds over 12 yrs (0.4/yr) · Last round Series D (Nov 2024)
Innovation: 226 patents (top 11% of patent-holders) · 118 filings since 2022 vs 76 in 2017-21
Funding rounds
- Nov 2024Series D$34.5M
- Apr 2024Series D$55.2M
- Mar 2022Series D—
- Nov 2020Series C$50M
Investors
Lilly Asia Ventures, Cenova, 6 Dimensions Capital, ShenZhen GTJA Investment Group, Xicheng Jinrui, Yangzhou Guojin Investment Group
#12
Public · Zhongshan, Guangdong Province · founded 2012 · 2520 employees$195Mraised▾
Public · Zhongshan, Guangdong Province · founded 2012 · 2520 employees
Developer of antibody drug conjugates for the treatment of broad spectrum diseases. The company utilizes proprietary Tetrabody technology to develop pipeline of products for cancer, autoimmune disease, inflammation, metabolic disease, and other therapeutic fields.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 20%Growth
top 35%News
top 39%Market
top 40%Moat
top 48%Talent
bottom 41%Funding: Raised $195M across 4 rounds · 4 rounds over 11 yrs (0.4/yr) · Last round Post IPO (Oct 2024)
Growth: Fresh capital in last 24 mo
News: 2 BI events in 12 mo (of 4 tracked, 3 types) · Top themes: IPO, Leadership
Audience (LinkedIn): 6k LinkedIn followers — 2.1% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 awards announced in 12 mo
Funding rounds
- Oct 2024Post IPO$249.9M
- Nov 2019Series D$150M
- Oct 2018Series C—
- Aug 2017Series B$45M
Founders & team
Investors
Ally Bridge Group, Shenzhen Capital Group, Triwise Capital, CCB Principal Asset Management, ShenZhen GTJA Investment Group, Qianhaifund
Tech stack
AzureAzure Front DoorBaidu Analytics (百度统计)BootstrapFont AwesomeGoogle Analytics
Funding & investor landscape
$16.2Btotal disclosed funding
142companies funded
294disclosed rounds
5rounds last 90 days
Most active investors
Qiming Venture Partners17 rounds
Notable founders
HH Ting
Co-Founder And Chief Strategy Officer · Full-Life Technologies
HongHoi Ting
Co-Founder · Full-Life Technologies
He Xiaowen
Co-Founder · OriCell Therapeutics
Xiaohu Zhang
Co-Founder & CEO · Accropeutics
Sudan He
Co-Founder · Accropeutics
George Chen
Founder & CEO · D3 Bio
Maoliang Li
Co-Founder & Chairman · CNRT
Jihui Qian
Co-Founder · CNRT
Michael Yang
Co-Founder And Scientific Advisor · Prenetics
Danny Yeung
Co-Founder & CEO · Prenetics
Peter Luo
Founder & CEO · Adagene
Siyi Hu
Co-Founder · Phrontline Biopharma
Prism market signals · China · country-scoped Prism corpus, 3,728,296 docs
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · China
How research on Oncology & Cancer Therapeutics is moving in China
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 18,693 China-affiliated papers.
research sentiment over time
201120192026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 38% → 66% across 2011–2026.
top research entities
- Chinese Academy of Medical Sciences & Peking Union Medical College934
- Sun Yat-sen University906
- Shanghai Jiao Tong University687
- Chinese Academy of Sciences684
- Fudan University672
leading researchers
Yang Liu · Yu Zhang · Wei Wang · Jing Li · Yi Zhang · Yan Zhang · Jing Wang · Hao Zhang
▲
Breakthroughs6,368 · 34%
▼ 38%→34% share
▼0.9× share momentum2 median citations96% since 2021mostly methods-led
Tumor microenvironment breakthrough research from China surged 98-fold (31→3,035 papers), signaling rapidly intensifying mechanistic discovery.
rising sub-themes (early→recent)
- Tumor microenvironment31→3035
- Immune system14→2292
- Immunotherapy14→2289
- Cancer research44→2062
- Cancer immunotherapy11→1149
Newly emergingTranscriptome 0→309 · Breast cancer 0→268 · Reprogramming 0→248
Landmark TIMER2.0 for analysis of tumor-infiltrating immune cells · 5,542 cites
◆
Advancements9,105 · 49%
▲ 48%→49% share
▲1.0× share momentum2 median citations97% since 2021mostly empirical
Tumor microenvironment advancement papers rose 99-fold (50→4,931), dominating oncology progress output from Chinese institutions.
rising sub-themes (early→recent)
- Tumor microenvironment50→4931
- Immune system20→4189
- Immunotherapy18→3278
- Cancer research64→3230
- Cancer immunotherapy8→1252
Newly emergingTranscriptome 0→461 · Biomarker 0→371 · Gene 0→333
Landmark Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future · 2,188 cites
▼
Concerns1,568 · 8%
▲ 6%→8% share
▲1.3× share momentum3 median citations96% since 2021mostly reviews
Immunotherapy safety concerns are intensifying — Chinese papers flagged rising issues, growing from 4 to 822 with CAR-T newly flagged.
rising sub-themes (early→recent)
- Immunotherapy4→822
- Tumor microenvironment8→814
- Immune system2→673
- Cancer immunotherapy3→366
- Cancer research4→318
Newly emergingChimeric antigen receptor 0→96 · Reprogramming 0→86 · Breast cancer 0→62
Landmark The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells a · 2,721 cites
RESEARCH HOTSPOTS · China
Where oncology is researched across China
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Shanghai2463 · +0.61
Beijing2176 · +0.63
Guangzhou/Shenzhen2040 · +0.61
Nanjing1254 · +0.62
Wuhan1137 · +0.54
Hangzhou1032 · +0.57
Harbin500 · +0.64
Hefei236 · +0.71
PATENT SIGNAL · China
Who's filing oncology patents in China
China oncology patent filing is accelerating — 182 filings from 110 assignees (2016–2025), led by 1globe Biomedical, Joint Biosciences SH, Yafei Shanghai Biology Medicine ; annual filings 2→40.
182 filings110 assigneespeak 40/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- 1globe Biomedical10
- Joint Biosciences SH9
- Yafei Shanghai Biology Medicine 9
- 1globe Health INST8
- Remegen8
- Jiangsu Hengrui Medicine8
- CHIA TAI Tianqing Pharmaceutical7
- Suzhou Suncadia Biopharmaceutica6
Common questions
How many Oncology companies are there in China?
Radar tracks 320 indexable Oncology companies headquartered in China that meet our profile-completeness bar.
What is the total funding raised by Oncology companies in China?
The Oncology companies in China on this list have raised a combined $16.2B in disclosed equity funding across 142 funded companies.
Which is the highest-funded Oncology company in China?
Abogen Biosciences is the highest-funded Oncology company in China, with $1.1B in disclosed equity funding.
How many Oncology companies in China are funded?
142 of the 320 Oncology companies in China on this list have disclosed at least one equity funding round.
How many Oncology unicorns are there in China?
3 Oncology companies in China on this list are valued at $1B or more.
Who are the top investors in China Oncology companies?
The most active investors in China Oncology companies on this list include Lilly Asia Ventures, Qiming Venture Partners, CDH, Hillhouse, Orbimed.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.